The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with ...
In a statement sent to Pharmaceutical Executive, AMCP CEO Susan A. Cantrell, MHL, RPh, CAE, said, “Although President Trump’s ...
In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI identifies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback